Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Intracellular delivery of a novel multiepitope peptide vaccine by an amphipathic peptide carrier enhances cytotoxic T-cell responses in HLA-A*201 mice.

Dakappagari NK, Sundaram R, Rawale S, Liner A, Galloway DR, Kaumaya PT.

J Pept Res. 2005 Feb;65(2):189-99.

PMID:
15705163
2.

Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities.

Dakappagari NK, Lute KD, Rawale S, Steele JT, Allen SD, Phillips G, Reilly RT, Kaumaya PT.

J Biol Chem. 2005 Jan 7;280(1):54-63. Epub 2004 Oct 26.

3.

A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses.

Dakappagari NK, Pyles J, Parihar R, Carson WE, Young DC, Kaumaya PT.

J Immunol. 2003 Apr 15;170(8):4242-53.

4.

Synthetic peptides as cancer vaccines.

Sundaram R, Dakappagari NK, Kaumaya PT.

Biopolymers. 2002;66(3):200-16. Review.

PMID:
12385038
5.

Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine.

Dakappagari NK, Douglas DB, Triozzi PL, Stevens VC, Kaumaya PT.

Cancer Res. 2000 Jul 15;60(14):3782-9.

Supplemental Content

Loading ...
Support Center